切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (05) : 232 -235. doi: 10.3877/cma.j.issn.2095-3216.2015.05.003

所属专题: 文献

专家论坛

C1q肾病的诊断及治疗
倪兆慧1,(), 金海姣1, 徐维佳1   
  1. 1. 200127 上海交通大学医学院附属仁济医院肾脏科
  • 出版日期:2015-10-28
  • 通信作者: 倪兆慧
  • 基金资助:
    国家自然科学基金(81370794); 国家科技支撑计划课题(2011BAI10B08)

Diagnosis and treatment of C1q nephropathy

Zhaohui Ni1,(), Haijiao Jin1, Weijia Xu1   

  1. 1. Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
  • Published:2015-10-28
  • Corresponding author: Zhaohui Ni
  • About author:
    Corresponding author: Ni Zhaohui, Email:
引用本文:

倪兆慧, 金海姣, 徐维佳. C1q肾病的诊断及治疗[J/OL]. 中华肾病研究电子杂志, 2015, 04(05): 232-235.

Zhaohui Ni, Haijiao Jin, Weijia Xu. Diagnosis and treatment of C1q nephropathy[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(05): 232-235.

C1q肾病是一种以系膜增生为主的肾小球疾病,其特点为免疫荧光染色可见系膜区高强度C1q沉积,电镜下可见系膜区电子致密物沉积,根据组织病理学特点主要分为3类,包括微小病变(MCD)、局灶节段性肾小球硬化(FSGS)和免疫介导的增生性肾小球肾炎。C1q肾病的临床表现具有多样性,可表现为肾炎或肾病范围内蛋白尿,伴有或不伴有血尿和肾功能损伤。虽然目前糖皮质激素是治疗C1q肾病的主要方法,但多数研究认为C1q肾病对糖皮质激素治疗反应较差。中西医结合治疗有望提高C1q肾病的疗效。

C1q nephropathy is a glomerular disorder with prominent mesangial proliferation. It is characterized by mesangial dense deposits under electron microscopy and C1q deposits under immunofluorescence microscopy. The histologic pattern of C1q nephropathy can be divided into three kinds: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and immune-mediated proliferative glomerulonephritis. Its clinical presentation is heterogenous, ranging from nephritic to nephrotic proteinuria, with or without hematuria and renal insufficiency. Glucocorticoids remain the mainstay of treatment. Most studies indicated poor response of C1q nephropathy to glucocorticoids. The treatment of integrated Chinese and western medicine for C1q nephropathy is promising.

1
Malleshappa P, Vankalakunti M. Diverse clinical and histology presentation in C1q nephropathy [J]. Nephrourol Mon, 2013, 5(3): 787-791.
2
Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome [J]. Am J Kidney Dis, 1985, 6(2): 103-110.
3
Markowitz GS, Schwimmer JA, Stokes MB, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis [J]. Kidney Int, 2003, 64(4): 1232-1240.
4
Meyrier A, Gerald BA. Minimal change variants: mesangial proliferation; IgM nephropathy[DB/OL]. UpToDate, 2014,

URL    
5
Kersnik Levart T, Kenda RB, Avgustin Cavic M, et al. C1Q nephropathy in children [J]. Pediatr Nephrol, 2005, 20(12): 1756-1761.
6
van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, et al. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells [J]. J Am Soc Nephrol, 1996, 7(4): 573-581.
7
Thomas DB. Focal segmental glomerulosclerosis: a morphologic diagnosis in evolution [J]. Arch Pathol Lab Med, 2009, 133(2): 217-223.
8
Isaac J, Shihab FS. De novo C1q nephropathy in the renal allograft of a kidney pancreas transplant recipient: BK virus-induced nephropathy [J]? Nephron, 2002, 92(2): 431-436.
9
Mii A, Shimizu A, Masuda Y, et al. Current status and issues of C1q nephropathy [J]. Clin Exp Nephrol, 2009, 13(4): 263-274.
10
Vizjak A, Ferluga D, Rozic M, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy [J]. J Am Soc Nephrol, 2008, 19(11): 2237-2244.
11
Srivastava T, Chadha V, Taboada EM, et al. C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis [J]. Pediatr Nephrol, 2000, 14(10-11): 976-979.
12
Emanicipator SN. Benign essential hematuria, IgA nephropathy, and Alport syndrome [J]. Renal Biopsy Interpretation, 1996, 10(2): 147-180.
13
Srivastava T, Chadha V. C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis [J]. Clin Exp Nephrol, 2009, 13(4): 263-274.
14
Kersnik Levart T, Kenda RB, Avgustin Cavic M, et al. C1Q nephropathy in children [J]. Pediatr Nephrol, 2005, 20(12): 1756-1761.
15
Hisano S, Fukuma Y, Segawa Y, et al. Clinicopathologic correlation and outcome of C1q nephropathy [J]. Clin J Am Soc Nephrol, 2008, 3(6): 1637-1643.
16
赵三龙,黄松明,朱春华,等. 儿童C1q肾病的临床病理特点及治疗[J].中华肾脏病杂志,2011,12(27): 877-883.
17
Sinha A, Nast CC, Hristea I, et al. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy [J]. Clin Exp Nephrol, 2011, 15(1): 164-170.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[6] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[7] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[8] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[9] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[10] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[11] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[12] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[13] 吴天宇, 刘子璇, 杨浦鑫, 贾思明, 丁凯, 程晓东, 李泳龙, 陈伟, 吕红芝, 张奇. 腰椎间盘突出症保守治疗进展[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 379-384.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?